300+ investors in your industry, stage, and region Get
Any industry
Community
Proptech
Biotech
Climate
Artificial Intelligence
Media (Entertainment)
Impact
FinTech
Marketplace
EdTech
Consumer
Agriculture (AgTech)
Web3
Clean Energy
B2B
Organic Food
Big Data
Video Games
Payments
Celebrity
Franchise
Mobile
Local
Social Network
Platforms
Crowdfunding
CleanTech
Film
Theatre
Life Science
Non Profit
Transportation
Gaming
Energy
Hardware
Health Care
Enterprise
Sustainability
Venture Capital
Restaurants
Fashion
Real Estate
Retail
Infrastructure
Mobile Apps
Beauty
LGBT
Publishing
Sporting Goods
Oil and Gas
Education
Renewable Energy
Food and Beverage
Cryptocurrency
Finance
Financial Services
Photography
Art
Medical
Digital Media
Music
Internet
Social Media
Manufacturing
Facebook
Blockchain
Legal
Android
Social Impact
Google
Construction
Sports
eSports
Enterprise Software
Email
Wellness
Hospitality
Travel
Fitness
Mobile Advertising
Cannabis
Recruiting
Biotechnology
Medical Device
Wine and Spirits
Automotive
Social
InsurTech
SaaS
Software
Any country
Qatar
South Korea
Africa
Asia
LATAM
Europe
Oceania
Middle East
Ireland
Singapore
Indonesia
Spain
Saudi Arabia
Belarus
Belgium
Colombia
Denmark
Ecuador
Czech Republic
Estonia
Ghana
Ethiopia
Finland
Barbados
Italy
Jersey
Cayman Islands
Mali
Malaysia
Mauritius
Poland
Rwanda
Togo
Slovenia
San Marino
Tanzania
Thailand
Uruguay
Venezuela
Portugal
Azerbaijan
Namibia
Bolivia
Latvia
Cyprus
New Zealand
United States
Germany
Australia
India
United Kingdom
Canada
China
South Africa
Brazil
Japan
Sri Lanka
Vietnam
Argentina
Armenia
Austria
Bangladesh
Bahrain
Bulgaria
Bermuda
Chile
Cameroon
Switzerland
Belize
Costa Rica
Algeria
Georgia
Egypt
Hong Kong
Gibraltar
Faroe Islands
Greece
Croatia
France
Hungary
Kuwait
Israel
Lebanon
Cambodia
Kenya
Jordan
Lithuania
Liberia
Liechtenstein
Myanmar
Kazakhstan
Morocco
Norway
Mexico
Panama
Malta
Peru
Philippines
Nicaragua
Pakistan
Russian Federation
Romania
Sweden
Serbia
Seychelles
Turkey
Puerto Rico
Sierra Leone
Senegal
Tunisia
Tajikistan
El Salvador
Uganda
Zambia
Uzbekistan
Taiwan
Ukraine
Zimbabwe
Bahamas
Guatemala
Iraq
Iceland
Nigeria
United Arab Emirates
Honduras
Isle of Man
Luxembourg
Oman
Angel Investors
VC Funds
All Investors
Download Find emails Save list
Open database

Top 50 Biotechnology Startup Investors in Europe (October 2023)

The most active venture capital funds and angel investors investing in Europe Biotechnology startups. This investor list is updated monthly from the Shizune investor database, ranked by number of investments in Europe Biotechnology startup companies. Find investors to raise a Seed, Series A or Series B round with Shizune.
Investor Relevant Deals Geography Stage Focus Round Size
Sofinnova Partners
VC Fund
55 France, United States, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Medical $4.4M–$57M
UK Innovation & Science Seed Fund
VC Fund
50 United Kingdom, United States Seed, Series A Biotechnology, Health Care, Medical $246k–$10M
Bpifrance
VC Fund
47 France, United States, Switzerland Seed, Series A Software, Health Care, Information Technology $643k–$29M
Parkwalk Advisors
VC Fund
40 United Kingdom, United States, Philippines Seed, Series A, Series B Biotechnology, Health Care, Software $860k–$33M
High-Tech Grunderfonds
VC Fund
39 Germany, Switzerland, United States Seed, Series A Software, Information Technology, Biotechnology $665k–$16M
Novo Holdings
VC Fund
36 United States, Denmark, United Kingdom Series A, Series B, Series C Biotechnology, Health Care, Medical $6.5M–$125M
Oxford Technology Management
VC Fund
34 United Kingdom, United States Seed, Series A Biotechnology, Health Care, Software $25k–$7.4M
Scottish Investment Bank
VC Fund
34 United Kingdom, United States, France Seed, Series A Software, Biotechnology, Information Technology $307k–$7.6M
Oxford Science Enterprises
VC Fund
34 United Kingdom, United States, The Netherlands Seed, Series A Biotechnology, Health Care, Software $1M–$34M
Scottish Enterprise
VC Fund
33 United Kingdom, United States, Japan Grant, Seed Biotechnology, Software, Health Care $92k–$4.1M
Kurma Partners
VC Fund
30 France, Spain, Switzerland Series A, Seed, Series B Health Care, Biotechnology, Medical $2.1M–$80M
Oxford Capital
VC Fund
29 United Kingdom, United States, France Seed, Series A Software, Mobile, Health Care $1.6M–$13M
Seventure Partners
VC Fund
28 France, United States, Germany Series A, Series B Biotechnology, Health Care, Software $2.4M–$35M
Catapult Ventures
VC Fund
27 United Kingdom, United States, Israel Seed, Series A Health Care, Biotechnology, Pharmaceutical $123k–$26M
Enterprise Ireland
VC Fund
27 Ireland, United States, United Kingdom Seed, Series A Software, Health Care, Information Technology $429k–$12M
Boehringer Ingelheim Venture Fund
VC Fund
26 United States, Germany, Belgium Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $1.3M–$50M
Jonathan Milner
Angel
25 United Kingdom, United States, Canada Seed, Series A, Series B Biotechnology, Health Care, Medical $430k–$50M
Mercia Fund Managers
VC Fund
25 United Kingdom, United States, Hungary Seed, Series A Software, Health Care, Biotechnology $184k–$21M
Karista
VC Fund
24 France, United States, Norway Seed, Series A, Series B Software, Biotechnology, Health Care $321k–$32M
GO CAPITAL
VC Fund
24 France, Canada, Israel Seed, Series A Biotechnology, Software, Health Care $504k–$6.4M
Auriga Partners
VC Fund
22 France, United States, Switzerland Series B, Series A Biotechnology, Health Care, Medical $2.1M–$31M
Archangels
VC Fund
21 United Kingdom, United States Seed, Series A Software, Biotechnology, Health Care $123k–$7M
Epidarex Capital
VC Fund
21 United Kingdom, United States, Germany Series A, Seed, Series B Biotechnology, Therapeutics, Health Care $536k–$38M
Idinvest Partners
VC Fund
20 France, United States, Spain Series B, Series A Biotechnology, Software, Health Care $3.2M–$53M
M Ventures
VC Fund
20 United States, Switzerland, United Kingdom Series A, Series B, Seed Biotechnology, Health Care, Therapeutics $2.1M–$67M
AlbionVC
VC Fund
20 United Kingdom, United States, France Series A, Seed Software, Health Care, Artificial Intelligence $1.8M–$13M
Omnes Capital
VC Fund
20 France, United States, Belgium Series A, Series B Software, Biotechnology, Health Care $3.2M–$37M
MIG Capital
VC Fund
20 Germany, Austria, Canada Series A, Series B Biotechnology, Health Care, Pharmaceutical $1.6M–$26M
Deepbridge Capital
VC Fund
19 United Kingdom, Australia, Singapore Seed, Series A Health Care, Biotechnology, Medical $143k–$10M
Caixa Capital Risc
VC Fund
19 Spain, United States, United Kingdom Seed, Series A Software, Biotechnology, E-Commerce $246k–$17M
GM&C Life Sciences Fund
VC Fund
19 United Kingdom, Italy, Germany Seed, Series A Health Care, Biotechnology, Medical $61k–$903k
BioInnovation Institute
VC Fund
19 Denmark, Germany, Switzerland Convertible Note, Debt Financing, Pre-Seed Biotechnology, Medical, Health Care $504k–$1.8M
Newable Private Investing
VC Fund
18 United Kingdom, United States Seed, Series A Software, Health Care, Biotechnology $184k–$3.8M
Centre for the Development of Industrial Technology (CDTI)
VC Fund
18 Spain, United States, France Seed, Grant Biotechnology, Health Care, Software $123k–$4.4M
Development Bank of Wales
VC Fund
18 United Kingdom, Australia, United States Seed, Debt Financing Health Care, Software, Biotechnology $12k–$2.8M
HealthCap
VC Fund
18 United States, Sweden, France Series B, Series A Biotechnology, Health Care, Medical $5.5M–$55M
IP Group
VC Fund
17 United Kingdom, United States, Australia Seed, Series A, Series B Health Care, Biotechnology, Therapeutics $369k–$61M
Kelvin Capital
VC Fund
17 United Kingdom, United States Seed, Series A Health Care, Biotechnology, Manufacturing $139k–$24M
AdBio partners
VC Fund
16 France, Belgium, Spain Seed, Series A Biotechnology, Health Care, Pharmaceutical $2.1M–$29M
TRICAPITAL
VC Fund
16 United Kingdom, France Seed, Series B Biotechnology, Software, Health Care $172k–$6.4M
NRW.BANK
VC Fund
15 Germany, United States Seed, Series A, Series B Biotechnology, Software, Health Care $107k–$13M
Forbion Capital Partners
VC Fund
15 United States, United Kingdom, The Netherlands Series B, Series A, Series C Biotechnology, Health Care, Medical $4.5M–$115M
Par Equity
VC Fund
15 United Kingdom, United States, Brazil Seed, Series A Software, Information Technology, Computer $244k–$7.9M
Wellcome Trust
VC Fund
15 United States, United Kingdom, Germany Grant, Series C Biotechnology, Health Care, Pharmaceutical $1.2M–$90M
Elaia
VC Fund
15 France, United States, Spain Seed, Series A, Series B Software, Information Technology, Artificial Intelligence $857k–$27M
Kernel Capital
VC Fund
15 Ireland, United Kingdom, France Seed, Series A Software, Information Technology, Health Care $536k–$9M
Cambridge Angels group
VC Fund
15 United Kingdom, United States, Estonia Seed, Series A Software, Health Care, Biotechnology $244k–$16M
EQT life science
VC Fund
15 United States, The Netherlands, Switzerland Series A, Series B, Series C Biotechnology, Health Care, Therapeutics $5.4M–$70M
Vaekstfonden
VC Fund
15 Denmark, United States, United Kingdom Seed, Pre-Seed Software, Information Technology, SaaS $431k–$4.6M
Ysios Capital
VC Fund
15 Spain, United States, Switzerland Series A, Series B, Series C Biotechnology, Health Care, Medical $2.1M–$48M
Access all 50 investors in Europe Biotechnology startups.

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Investor list

Sofinnova Partners
VC Fund · Paris, Ile-de-France, France · 55 investments in Europe Biotechnology startups, 21 in the past 12 months

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: France, United States, United Kingdom

Investor stats

  • Total investments: 232
  • Round size: Series A $4.4M–$53M; Series B $7M–$57M; Series C $10M–$54M
  • Lead/follow: 47% lead, 53% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
  • Sitryx Therapeutics — Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism.Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.
  • Tenpoint Therapeutics — Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics.
Show all investments...

UK Innovation & Science Seed Fund
VC Fund · Harwell, Oxfordshire, United Kingdom · 50 investments in Europe Biotechnology startups, 13 in the past 12 months

UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States

Investor stats

  • Total investments: 96
  • Round size: Seed $246k–$2.9M; Series A $2.7M–$10M
  • Lead/follow: 32% lead, 68% follow
  • Last fund: May invest from a new fund soon — last raise in 2014

Portfolio highlights

  • Machine Discovery — Machine Discovery is a University of Oxford spin-out commercializing new machine learning technology. We leverage proprietary neural network technology to accelerate expensive calculations — and we do it with minimal data and 99.9% fidelity.
  • Pencil Biosciences — Next Generation Genome Editing Tool
  • Laverock Therapeutics — Laverock Therapeutics is developing a gene silencing platform for the creation of programmable, allogeneic cell therapies.
Show all investments...

Bpifrance
VC Fund · Maisons-alfort, Ile-de-France, France · 47 investments in Europe Biotechnology startups, 117 in the past 12 months

Bpifrance provides financial solutions for companies that are booting up the listing on the stock exchange and credit equity. It includes OSEO, CDC Entreprises, FSI, and FSI Regions to offer in your area of financial solutions at every stage of the life of your business.Bpifrance was founded in 2012 and is based in Maisons-alfort, Ile-de-France,France.

Show more...

Investment focus

  • Industry: Software, Health Care, Information Technology
  • Stage:Seed, Series A
  • Geography: France, United States, Switzerland

Investor stats

  • Total investments: 667
  • Round size: Seed $643k–$5.4M; Series A $2M–$29M
  • Lead/follow: 22% lead, 78% follow
  • Last fund: Likely still investing — fund raised in 2021

Portfolio highlights

  • Nonna Lab — Make the Most. Le laboratoire qui vous rend la vie meilleure.
  • Altior — Altior is an IT company that offers cloud industrial management software and ERP solution.
  • Umiami — Umiami Technologies is a leader in plant-based meat. Our proprietary technology allows us to create clean-label and incredibly tasty foods.
Show all investments...

Parkwalk Advisors
VC Fund · London, England, United Kingdom · 40 investments in Europe Biotechnology startups, 12 in the past 12 months

Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Seed, Series A, Series B
  • Geography: United Kingdom, United States, Philippines

Investor stats

  • Total investments: 211
  • Round size: Seed $860k–$3.7M; Series A $1.5M–$12M; Series B $1.8M–$33M
  • Lead/follow: 26% lead, 74% follow
  • Last fund: Likely still investing — fund raised in 2022

Portfolio highlights

  • RoboK — A Cambridge University spin-out building cost-effective 3D sensing software technology
  • Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
  • PharmEnable — Designing the next generation of small molecule drugs. Replicating the specificity of biologics in the scalable form of a small molecule.
Show all investments...

High-Tech Grunderfonds
VC Fund · Bonn, Nordrhein-Westfalen, Germany · 39 investments in Europe Biotechnology startups, 64 in the past 12 months

High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven startups. With EUR 895.5 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge more than 500 startups since 2005. Driven by their expertise, entrepreneurial spirit, and passion, its teamof experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech startups in a range of sectors, including software, media, internet, hardware, automation, health care, chemistry, and life sciences.To date, external investors have injected over EUR 2 billion into the HTGF portfolio via about 1,400 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies. Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, the KfW Banking Group, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, FOND OF Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, Postbank, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.

Show more...

Investment focus

  • Industry: Software, Information Technology, Biotechnology
  • Stage:Seed, Series A
  • Geography: Germany, Switzerland, United States

Investor stats

  • Total investments: 373
  • Round size: Seed $665k–$5.1M; Series A $1.5M–$16M
  • Lead/follow: 31% lead, 69% follow
  • Last fund: Likely still investing — fund raised in 2022

Portfolio highlights

  • Inovedis — Inovedis offers innovative solutions in medical technology that contribute both to optimized patient care as well as time and cost reductions in the healthcare sector.
  • Resourcify — Mein Recycling is developed by Resourcify GmbH from Hamburg. The app is the easiest solution for businesses to easily manage all of their waste, collections, and recyclers in one app, and for waste management companies to seamlessly connect with their customers online. Their vision is zero-waste: enabled with the digital transformation of the wastesector as the foundation for the circular economy.
  • traceless materials — traceless materials offer a holistically sustainable alternative to plastics: 100% biobased on plant residues, compostable under natural conditions, and free of toxic chemicals. For a future free of pollution and waste!
Show all investments...

Novo Holdings
VC Fund · Hellerup, Hovedstaden, Denmark · 36 investments in Europe Biotechnology startups, 19 in the past 12 months

Novo Holdings is a world-leading life science investor with a focus on creating long-term value.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: United States, Denmark, United Kingdom

Investor stats

  • Total investments: 225
  • Round size: Series A $6.5M–$63M; Series B $12M–$125M; Series C $12M–$105M
  • Lead/follow: 36% lead, 64% follow
  • Last fund: May invest from a new fund soon — last raise in 2018

Portfolio highlights

  • Octave — Octave is a national behavioral health practice that’s creating a new standard for care delivery that’s both high-quality and accessible to more people. With in-person and virtual clinics in California and New York, the company offers personalized care plans that can include individual therapy, couples therapy, and groups, while pioneeringrelationships with payers to make care more affordable through insurance. Grounded in science, Octave enables clients to experience profound change that is as measurable as it is meaningful.
  • Acesion Pharma — Acesion Pharma ApS is a Danish biotech company founded in 2011 and based in Copenhagen. Acesion Pharma develops more efficacious and safe drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia.
  • Alentis Therapeutics — Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases.
Show all investments...

Oxford Technology Management
VC Fund · Oxford, Oxfordshire, United Kingdom · 34 investments in Europe Biotechnology startups

Oxford Technology's SEIS fund and EIS fund enable private investors to access high growth technology startup opportunities and support UK innovation. SEIS and EIS tax reliefs offer downside protection, whilst gains can be tax free.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States

Investor stats

  • Total investments: 104
  • Round size: Seed $25k–$2M; Series A $737k–$7.4M
  • Lead/follow: 7% lead, 93% follow
  • Last fund: May invest from a new fund soon — last raise in 2012

Portfolio highlights

  • OxCan — Enabling curative cancer treatment through early detection
  • Machine Discovery — Machine Discovery is a University of Oxford spin-out commercializing new machine learning technology. We leverage proprietary neural network technology to accelerate expensive calculations — and we do it with minimal data and 99.9% fidelity.
  • MitoRx Therapeutics — Developing revolutionary mitochondrial-protective therapeutics which reverse mitochondrial dysfunction to arrest decline in muscular dystrophy and neurodegeneration. MitoRx Therapeutics' first-in-class first-in-target platform has potential to arrest the progression of some of the most challenging diseases.
Show all investments...

Scottish Investment Bank
VC Fund · Glasgow, Glasgow City, United Kingdom · 34 investments in Europe Biotechnology startups

Our Entrepreneurship team (formerly the Scottish Investment Bank) helps you find sources of finance, engage with funders and secure investment to grow your business.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Information Technology
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States, France

Investor stats

  • Total investments: 195
  • Round size: Seed $307k–$2.5M; Series A $1.5M–$7.6M
  • Lead/follow: 10% lead, 90% follow
  • Last fund: May invest from a new fund soon — last raise in 2015

Portfolio highlights

  • Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
  • IOTech — Discover IOTech Systems, the open edge data platform for developing, deploying, and managing Industrial Edge applications at scale. Find out more here.
  • Administrate — Manage 100% of enterprise training operations with configurable training management software, designed to scale with your organization.
Show all investments...

Oxford Science Enterprises
VC Fund · Oxford, Oxfordshire, United Kingdom · 34 investments in Europe Biotechnology startups, 15 in the past 12 months

Oxford Sciences Innovation is the world’s largest university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companiestaking on challenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States, The Netherlands

Investor stats

  • Total investments: 123
  • Round size: Seed $1M–$6.8M; Series A $3.7M–$34M
  • Lead/follow: 41% lead, 59% follow

Portfolio highlights

  • Navenio — Navenio is a software technology company that provides location-based services for indoor environments via mobile applications. Its solution provides an improvement on other indoor localization technologies, having the ability to locate people without the need for implementing, managing, or surveying any new building hardware such as beacons orwi-fi. Navenio’s intelligent workforce solution unlocks significant improvements in the efficiency and workflow of staff and teams through automation that is carefully driven from real-world best practice.The company was founded in 2015 and is headquartered in Oxford, England.
  • AlveoGene — Welcome to AlveoGene Transforming Rare Respiratory Disease Outcomes Using Inhaled Gene Therapy More information
  • Sitryx Therapeutics — Sitryx is a biopharmaceutical company focused on regulating cell metabolism to develop first-in-class disease modifying therapeutics in immuno-oncology and immuno-inflammation. The company was co-founded by a team of world-leading scientists from the United States and Europe who have contributed significantly to the field of immunometabolism.Sitryx was founded in 2018 with seed funding from SV Health Investors and raised $30 million Series A funding from an international syndicate of specialist investors including SV Health Investors, Sofinnova Partners, Longwood Fund and GSK. The company has a pipeline of projects at multiple stages of drug discovery. Sitryx is headquartered in Oxford, UK.
Show all investments...

Scottish Enterprise
VC Fund · Glasgow, Glasgow City, United Kingdom · 33 investments in Europe Biotechnology startups, 24 in the past 12 months

Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.

Show more...

Investment focus

  • Industry: Biotechnology, Software, Health Care
  • Stage:Grant, Seed
  • Geography: United Kingdom, United States, Japan

Investor stats

  • Total investments: 193
  • Round size: Seed $197k–$2.9M; Grant $92k–$4.1M
  • Lead/follow: 35% lead, 65% follow

Portfolio highlights

  • Pneumagen — Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilitiesin glycobiology.
  • Microplate Dx — Microplate Dx is a developer of diagnostic technology aimed at significantly reducing fatalities caused by drug-resistant infections.Microplate Dx, an award-winning spinout company from the University of Strathclyde in Glasgow, focuses on creating innovative diagnostic solutions to combat the significant global health challenge of antimicrobialresistance. Their technology revolves around the ingenious concept of employing highly sensitive biosensor electrodes, enhanced with miniaturized hydrogel deposits containing various antibiotics tailored to the specific infection being detected. The primary mission of Microplate DX is to proactively prevent and manage the proliferation of antimicrobial resistance on a global scale.
  • Rapscallion Soda — Award Winning, Fresh Fruit, Low Calorie Soft Drinks, Handmade in Scotland. Fresh batches made weekly. Free UK Mainland Delivery. International Shipping. Ginga Ninja | Burnt Lemon | Dry Lime | Scottish Rhubarb Soda | Scottish Strawberry Soda | Cranachan Soda | Blueberry Soda Love soda. Hate hangovers. Drink local.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Kurma Partners
VC Fund · Paris, Ile-de-France, France · 30 investments in Europe Biotechnology startups

Kurma Partners is a management company based in Paris, specializing in the financing of innovation in healthcare and biotechnology, from pre-creation to development capital. Kurma Partners, which manages the Kurma Biofund I, II funds and the Kurma Diagnostics fund, is one of the main players in the financing of therapeutic and medical innovationsin Europe, particularly through links with many institutes. research and prestigious hospitals.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Series A, Seed, Series B
  • Geography: France, Spain, Switzerland

Investor stats

  • Total investments: 95
  • Round size: Seed $2.1M–$7.5M; Series A $2.1M–$50M; Series B $4.1M–$80M
  • Lead/follow: 53% lead, 47% follow
  • Last fund: May invest from a new fund soon — raised $89M in 2020

Portfolio highlights

  • Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
  • Axithra — Saving lives and improving health economics through significant advancement of therapeutic drug monitoring (TDM).
  • Kiro — Kiro is an IT company that offers artificial intelligence, ergonomic design, and software development solutions for medical biology.
Show all investments...

Oxford Capital
VC Fund · Oxford, Oxfordshire, United Kingdom · 29 investments in Europe Biotechnology startups

Helping individuals and institutions invest in Venture Capital, Infrastructure and Media companies since 1999.

Show more...

Investment focus

  • Industry: Software, Mobile, Health Care
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States, France

Investor stats

  • Total investments: 133
  • Round size: Seed $1.6M–$3.6M; Series A $1.6M–$13M
  • Lead/follow: 28% lead, 72% follow
  • Last fund: May invest from a new fund soon — last raise in 2015

Portfolio highlights

  • Scan.com — Use scan.com to find the best medical imaging centers near you Find an MRI scan, CT scan, X-ray Scan, or other diagnostic imaging scan with scan.com.
  • HelloSelf — The UK's Trusted Online Private Clinical Therapy Service
  • Legislate — Legislate is an easy-to-use contract management platform which provides a suite of customisable contracts for businesses and landlords.
Show all investments...

Seventure Partners
VC Fund · Paris, Ile-de-France, France · 28 investments in Europe Biotechnology startups, 7 in the past 12 months

Seventure Partners is a French venture capital firm targeting in information and communication technology, and life sciences companies. It funds innovation and participates in the entrepreneurial adventure, alongside entrepreneurs and sharing their passion.Founded in 1997, Seventure Partners is one of the European leaders in venture capital, with€ 660 million under management as of December 31, 2016. It is an active partner of innovative companies that, according to the management team, show strong growth potential and evolving in two fields of activity: Digital Technologies and Life Sciences. With more than 20 employees, including some 15 investors, Seventure Partners has a proven track record and in-depth expertise in technology, entrepreneurship, and various private equity operations.Seventure's goal is to identify and support the development of tomorrow's European leaders in order to accelerate their growth. To do this, the firm provides entrepreneurs with the expertise, networks, and know-how of its internal team of investors.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Series A, Series B
  • Geography: France, United States, Germany

Investor stats

  • Total investments: 175
  • Round size: Series A $2.4M–$18M; Series B $3M–$35M
  • Lead/follow: 35% lead, 65% follow
  • Last fund: May invest from a new fund soon — last raise in 2019

Portfolio highlights

  • Sinay — Use the full potential of your data with intelligent solutions. Become more efficient on a daily basis and reduce your environmental impact.
  • Allozymes — Allozymes, Pte. Ltd. is a leading deep technology company applying innovative ultrahigh-throughput microfluidics technology to accelerate enzyme evolution and development. We developed sensitive, accurate, and generic assays for the detection of enzymatic reactions, proprietary microfluidic chips and proteomics technologies to take enzymedevelopment to the next level.
  • Vedanta Biosciences — Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Show all investments...

Catapult Ventures
VC Fund · Leicester, Leicester, United Kingdom · 27 investments in Europe Biotechnology startups

The team behind Catapult Ventures are among the most experienced venture capital investors in the UK.Their experience spans a range of sectors from healthcare and pharmaceuticals to luxury consumer brands, manufacturing and software, as well as all stages: from start-ups and pre-revenue IP developers to company floatation and billions of poundsin revenue. Their administration team is equally experienced with each member having more than 10 years experience in a venture capital environment.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Pharmaceutical
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States, Israel

Investor stats

  • Total investments: 96
  • Round size: Seed $123k–$985k; Series A $1.6M–$26M
  • Lead/follow: 26% lead, 74% follow
  • Last fund: May invest from a new fund soon — last raise in 2018

Portfolio highlights

  • Pickle Robot — We make robots that unload trucks without retrofitting the warehouse
  • Urban Machine — Salvaging the past to build the future- Stealth Startup
  • Pencil Biosciences — Next Generation Genome Editing Tool
Show all investments...

Enterprise Ireland
VC Fund · Dublin, Dublin, Ireland · 27 investments in Europe Biotechnology startups, 19 in the past 12 months

Enterprise Ireland is the government agency responsible for the development and funding of the indigenous business sector. Their mission is to accelerate the development of companies to achieve strong positions in global markets resulting in increased national and regional prosperity. It was founded in 1998 and headquartered in Dublin, Ireland.

Show more...

Investment focus

  • Industry: Software, Health Care, Information Technology
  • Stage:Seed, Series A
  • Geography: Ireland, United States, United Kingdom

Investor stats

  • Total investments: 383
  • Round size: Seed $429k–$2.9M; Series A $2M–$12M
  • Lead/follow: 15% lead, 85% follow
  • Last fund: May invest from a new fund soon — raised $1.1M in 2021

Portfolio highlights

  • CergenX — CergenX produces cutting-edge technology for the analysis of baby brain waves that can be used to identify brain injuries early in the newborn period.
  • Tailr — Redefining production for the clothing industry.
  • Recruitroo — Recruitroo is a international recruitment agency that uses technologies to streamline and improve the international recruitment process for both companies and candidates.
Show all investments...

Boehringer Ingelheim Venture Fund
VC Fund · Ingelheim Am Rhein, Rheinland-Pfalz, Germany · 26 investments in Europe Biotechnology startups

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: United States, Germany, Belgium

Investor stats

  • Total investments: 82
  • Round size: Seed $1.3M–$14M; Series A $3.8M–$29M; Series B $11M–$50M
  • Lead/follow: 49% lead, 51% follow
  • Last fund: May invest from a new fund soon — last raise in 2018

Portfolio highlights

  • DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team News See more Our Work OUR APPROACH ABOUT DIABETES
  • smartbax — We develop novel multi-targeted, antibacterial compounds with extraordinary potency against multi-drug resistant bacteria and difficult-to-treat biofilms.
  • Rewind Therapeutics — Rewind Therapeutics is a developer of novel therapeutics intended to facilitate the treatment for neurological diseases.The company's first-in-class remyelinating therapeutics block inhibitory signals that prevent the expansion and migration of oligodendrocyte stem cells in order to promote effective remyelination, enabling medicalpractitioners to treat patients suffering from multiple sclerosis and other myelin-related diseases with efficacy.
Show all investments...

Jonathan Milner
Angel · Cambridge, Massachusetts, United States · 25 investments in Europe Biotechnology startups

Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Seed, Series A, Series B
  • Geography: United Kingdom, United States, Canada

Investor stats

  • Total investments: 44
  • Round size: Seed $430k–$10M; Series A $1.8M–$18M; Series B $1.8M–$50M
  • Lead/follow: 25% lead, 75% follow

Portfolio highlights

  • Mogrify — Mogrify is pioneering a new class of in vivo reprogramming therapy and transforming the development of ex vivo cell therapy.
  • PharmEnable — Designing the next generation of small molecule drugs. Replicating the specificity of biologics in the scalable form of a small molecule.
  • Pencil Biosciences — Next Generation Genome Editing Tool
Show all investments...

Mercia Fund Managers
VC Fund · Henley In Arden, Warwickshire, United Kingdom · 25 investments in Europe Biotechnology startups, 8 in the past 12 months

Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.

Show more...

Investment focus

  • Industry: Software, Health Care, Biotechnology
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States, Hungary

Investor stats

  • Total investments: 119
  • Round size: Seed $184k–$1.8M; Series A $1.2M–$21M
  • Lead/follow: 69% lead, 31% follow
  • Last fund: May invest from a new fund soon — last raise in 2013

Portfolio highlights

  • CanSense — CanSense is a developer of an inexpensive and scalable blood test intended for early diagnosis of bowel cancer.
  • Workbuzz — Issue employee engagement surveys with WorkBuzz - a fast, simple, and flexible platform with expert consultancy. Try it now!
  • Centuro Global — Centuro Global helps you go global.We help startups, scaleups & corporates enter new markets around the world. All your international expansion needs are serviced from one platform, whether you need legal support, tax & accounting, HR, opening a bank account or finding office space, we can assist across the board.Our innovativeplatform, Centuro Connect, contains blueprints on how to do business in over 150 countries, provides live chat advice, and access to local experts around the world. Instead of losing time undertaking Google searches for relevant information and identifying trusted, cost-effective service providers, find all your solutions through Centuro Connect.Come to us for services including; Legal, Immigration, Intellectual Property, Scaling & Expansion, New Market Entry, Tax & Accounting and much more.Receive advice, find service providers, investors and like minded individuals, and seamlessly grow your business.Book a free consultation with us: www.centuroglobal.com
Show all investments...

Karista
VC Fund · Paris, Ile-de-France, France · 24 investments in Europe Biotechnology startups

Karista is an early-stage venture capital firm created in 2001 investing in Health, Digital, Tech, and NewSpace.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Health Care
  • Stage:Seed, Series A, Series B
  • Geography: France, United States, Norway

Investor stats

  • Total investments: 129
  • Round size: Seed $321k–$2.8M; Series A $1.1M–$4.3M; Series B $2.5M–$32M
  • Lead/follow: 12% lead, 88% follow
  • Last fund: Likely still investing — fund raised in 2021

Portfolio highlights

  • Bfore.AI — Starting from patented technology developed in years of research, BforeAi is the prediction service that looks for newly registered or morphed domains, and score their maliciousness looking at metadata and links to other bad guys.
  • Exotrail — Exotrail is an end-to-end space mobility operator. Our mission is to enable small satellites to move in space, optimise their deployment, increase their service performance, and reduce space pollution.
  • Look Up Space — Lookup space is the next global leader for space safety, security and sustainability
Show all investments...

GO CAPITAL
VC Fund · Rennes, Bretagne, France · 24 investments in Europe Biotechnology startups, 8 in the past 12 months

GO CAPITAL is a management company approved by the AMF and a member of AFIC. It is based in Rennes, and manages more than 130 million of assets by investing primarily in western France in innovative companies with high growth potential.

Show more...

Investment focus

  • Industry: Biotechnology, Software, Health Care
  • Stage:Seed, Series A
  • Geography: France, Canada, Israel

Investor stats

  • Total investments: 104
  • Round size: Seed $504k–$4.2M; Series A $1.7M–$6.4M
  • Lead/follow: 35% lead, 65% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • Abcely — Abcely is a biotech firm that is working on a novel anti-cancer medication.
  • Episto — Episto helps you collect ultra-authentic insights from your targets, anywhere in the world, simply and instantly
  • Kanta — Kanta provides an anti-money laundering technology that automates data gathering and processing operations while maintaining standard compliance. Kanta automates time-consuming activities and manages AML regulatory monitoring.
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
Auriga Partners
VC Fund · Paris, Ile-de-France, France · 22 investments in Europe Biotechnology startups

Since 1998, AURIGA PARTNERS, an independent Venture Capital firm, has been managing several early stage funds specializing in Information Technology and Life Sciences.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series A
  • Geography: France, United States, Switzerland

Investor stats

  • Total investments: 126
  • Round size: Series A $2.1M–$14M; Series B $3.8M–$31M
  • Lead/follow: 17% lead, 83% follow
  • Last fund: May invest from a new fund soon — raised $45M in 2013

Portfolio highlights

  • Patrowl — Identify and harden your External Security Posture with the leader. Let us manage time-consuming tasks and focus on remediation
  • Exeliom — Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies.Exeliom develops anew class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system.The company was founded in 2016 and is headquartered in Dijon, France.
  • Vade Secure — Vade is a global leader in predictive email defense, protecting 1 billion inboxes worldwide. AI-based email security for Microsoft 365.
Show all investments...

Archangels
VC Fund · Edinburgh, Edinburgh, City of, United Kingdom · 21 investments in Europe Biotechnology startups, 6 in the past 12 months

Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Health Care
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States

Investor stats

  • Total investments: 72
  • Round size: Seed $123k–$2.7M; Series A $1.5M–$7M
  • Lead/follow: 54% lead, 46% follow

Portfolio highlights

  • Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
  • Cytomos — Cytomos develops and provides integrated, predictive analytics systems for intelligent bioprocessing in biopharma and cell therapy domains.
  • Administrate — Manage 100% of enterprise training operations with configurable training management software, designed to scale with your organization.
Show all investments...

Epidarex Capital
VC Fund · Bethesda, Maryland, United States · 21 investments in Europe Biotechnology startups

Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.

Show more...

Investment focus

  • Industry: Biotechnology, Therapeutics, Health Care
  • Stage:Series A, Seed, Series B
  • Geography: United Kingdom, United States, Germany

Investor stats

  • Total investments: 39
  • Round size: Seed $536k–$8M; Series A $2M–$24M; Series B $2.4M–$38M
  • Lead/follow: 56% lead, 44% follow
  • Last fund: May invest from a new fund soon — last raise in 2019

Portfolio highlights

  • Nyra Medical — MitraPlug has created a catheter-plug technology for repairing a leaky mitral valve in the heart.This adjustable device needs only a two-inch surgical incision and can be inserted directly into the heart. Then the cardiologist can use the catheter to adjust the size and position of the plug to correct the leakage. When correctly fitted, thecatheter is removed, and the incision is closed, leaving only a small scar.
  • RapidPulse — RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinoutof Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry
  • Transine Therapeutics — Transine Therapeutics is a private biotechnology company focused on the development of a novel class of therapeutic RNAs that can upregulate protein expression with an unprecedented level of control and specificity: the SINEUPs®. The company's pioneering technology is expected to offer an entirely unique mechanism of action for currentlyhard-to-treat diseases by massively extending the druggable proteome and allowing it to address diseases that have been beyond the reach of small molecules, conventional biologics, or gene therapies.
Show all investments...

Idinvest Partners
VC Fund · Paris, Ile-de-France, France · 20 investments in Europe Biotechnology startups

Idinvest Partners is a pan-European private equity manager focused on the low and middle-market segments. With over 6 billion euros under management, the company has developed several complementary areas of expertise, including equity investments in buyout deals focusing on both mid-size as well as young innovative European companies; primaryinvestments in European private equity funds focusing primarily on the middle market segment; secondary investments; mezzanine investments in Europe; and private equity consulting.Idinvest Partners’ recent success stories include Criteo, Clear2Pay, Meetic, Prosensa, Converteam, Kwik Fit, Lastminute.com, Dailymotion, Deezer, Talend, Synthesio, Menlook, Vestiaire Collective, Pretty Simple, Curse.com, Withings, Kantox, Secret Escapes, Happn, Peakon, Dayuse, Botify, Financefox, Azalead and many more.

Show more...

Investment focus

  • Industry: Biotechnology, Software, Health Care
  • Stage:Series B, Series A
  • Geography: France, United States, Spain

Investor stats

  • Total investments: 217
  • Round size: Series A $3.2M–$15M; Series B $7.4M–$53M
  • Lead/follow: 34% lead, 66% follow
  • Last fund: May invest from a new fund soon — raised $86M in 2021

Portfolio highlights

  • Corti — Corti offers a digital assistant, augmenting medics in improving patient outcomes and internal performance.
  • Coave Therapeutics — Coave Therapeutics is active in the field of gene therapies in rare ocular and CNS (Central Nervous System) diseases.
  • BreezoMeter — BreezoMeter offers personalized air quality & pollen data as well as active fire alerts with worldwide coverage & accuracy down to the street level.
Show all investments...

M Ventures
VC Fund · Amsterdam, Noord-Holland, The Netherlands · 20 investments in Europe Biotechnology startups, 17 in the past 12 months

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Seed
  • Geography: United States, Switzerland, United Kingdom

Investor stats

  • Total investments: 119
  • Round size: Seed $2.1M–$18M; Series A $6M–$42M; Series B $9.5M–$67M
  • Lead/follow: 39% lead, 61% follow

Portfolio highlights

  • CellFE — CellFE is a company developing a microfluidics based device to deliver gene-editing molecules. CellFE developed microfluidic device and process that can efficiently deliver gene-editing molecules into the human cells.
  • BeeOLED — BeeOLED’s technology enables OLED displays with significantly improved efficiency, brightness and operational stability at lower overall costs due to a less complex device structure.
  • Lightcast Discovery — Flexible control over droplet number, occupancy, location and movement. Enabling efficient, multi-step workflows with unprecedented flexibility.
Show all investments...

AlbionVC
VC Fund · London, England, United Kingdom · 20 investments in Europe Biotechnology startups, 9 in the past 12 months

AlbionVC supports visionary founders with long-term capital and scale-up expertise, and manages c. $1 billion of venture funds, invested in 50+ companies. AlbionVC is the technology investment arm of Albion Capital Group LLP. The technology team invest from seed through to Series B in high growth companies, predominantly in the UK. The team has a focus on B2B software and technology enabled services. AlbionVC %

Show more...

Investment focus

  • Industry: Software, Health Care, Artificial Intelligence
  • Stage:Series A, Seed
  • Geography: United Kingdom, United States, France

Investor stats

  • Total investments: 119
  • Round size: Seed $1.8M–$13M; Series A $3.2M–$12M
  • Lead/follow: 39% lead, 61% follow

Portfolio highlights

  • Umedeor — uMed is a technology platform embedded across a global network of healthcare providers that automates the process of building prospective, protocolized patient registries. This enables sites to participate in dozens of programmes simultaneously without increasing overhead or burden on staff. For life science companies, uMed provides access toregulator quality data, where patients within those datasets can be compliantly re-engaged to support the aims of R&D and post-market teams
  • tem. — In a few simple steps we can manage your renewable energy needs forever.
  • Ramp Growth — How many users will your mobile game acquire, and how much more will they pour into your virtual economy? Try Ramp to find out.
Show all investments...

Omnes Capital
VC Fund · Paris, Ile-de-France, France · 20 investments in Europe Biotechnology startups, 9 in the past 12 months

Omnes, "Powering Entrepreneurs" is a Leading private equity firm dedicated to energy transition and innovation.

Show more...

Investment focus

  • Industry: Software, Biotechnology, Health Care
  • Stage:Series A, Series B
  • Geography: France, United States, Belgium

Investor stats

  • Total investments: 152
  • Round size: Series A $3.2M–$21M; Series B $4M–$37M
  • Lead/follow: 31% lead, 69% follow
  • Last fund: May invest from a new fund soon — raised $407M in 2020

Portfolio highlights

  • Iktos — Iktos is the only company to offer generative modeling with built-in synthetic accessibility for successful drug discovery
  • DiogenX — We incorporated DiogenX with the objective to provide new therapeutic solutions for diabetic patients. With Patrick Collombat and the team, we are focused on developing a first-in-class regenerative treatment for type 1 diabetes. Benjamin Charles CEO See the team News See more Our Work OUR APPROACH ABOUT DIABETES
  • The Exploration Company — For Space & Non-Space Industries.
Show all investments...

MIG Capital
VC Fund · München, Bayern, Germany · 20 investments in Europe Biotechnology startups

Zusammen gestalten wir die Unternehmen von morgen.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Series A, Series B
  • Geography: Germany, Austria, Canada

Investor stats

  • Total investments: 80
  • Round size: Series A $1.8M–$9M; Series B $1.6M–$26M
  • Lead/follow: 46% lead, 54% follow
  • Last fund: May invest from a new fund soon — last raise in 2014

Portfolio highlights

  • AMSilk — AMSilk produces and distributes high-quality silk biopolymers for use in textile products, medical devices, and cosmetics.
  • mbiomics — mbiomics is a biotechnology company.
  • Look Up Space — Lookup space is the next global leader for space safety, security and sustainability
Show all investments...

Deepbridge Capital
VC Fund · Chester, Cheshire, United Kingdom · 19 investments in Europe Biotechnology startups

Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Seed, Series A
  • Geography: United Kingdom, Australia, Singapore

Investor stats

  • Total investments: 77
  • Round size: Seed $143k–$2.1M; Series A $1.8M–$10M
  • Lead/follow: 78% lead, 22% follow
  • Last fund: Likely still investing — raised $1.2M in 2022

Portfolio highlights

  • Circada — Innovative Circadian lighting reconnects the body clock with nature
  • Microplate Dx — Microplate Dx is a developer of diagnostic technology aimed at significantly reducing fatalities caused by drug-resistant infections.Microplate Dx, an award-winning spinout company from the University of Strathclyde in Glasgow, focuses on creating innovative diagnostic solutions to combat the significant global health challenge of antimicrobialresistance. Their technology revolves around the ingenious concept of employing highly sensitive biosensor electrodes, enhanced with miniaturized hydrogel deposits containing various antibiotics tailored to the specific infection being detected. The primary mission of Microplate DX is to proactively prevent and manage the proliferation of antimicrobial resistance on a global scale.
  • GenoMe Diagnostics — GenoME Diagnostics - We are developing a blood test for an earlier and more accurate diagnosis of ovarian cancer.GenoME Diagnostics .
Show all investments...

Caixa Capital Risc
VC Fund · Barcelona, Catalonia, Spain · 19 investments in Europe Biotechnology startups, 9 in the past 12 months

Caixa Capital Risc (CCR) is the VC arm of CriteriaCaixa which invests in innovative companies in their start-up and growth stages. The company has three specialised teams in the areas of Information Technology, Life Sciences, and Industrial technologies. Caixa Capital Risc currently manages more than €300m through 11 specialised vehicles.

Show more...

Investment focus

  • Industry: Software, Biotechnology, E-Commerce
  • Stage:Seed, Series A
  • Geography: Spain, United States, United Kingdom

Investor stats

  • Total investments: 135
  • Round size: Seed $246k–$3.2M; Series A $1.8M–$17M
  • Lead/follow: 42% lead, 58% follow
  • Last fund: Likely still investing — fund raised in 2021

Portfolio highlights

  • inari — INARI provides blockchain, machine learning and artificial intelligence technologies for the Insurance industry
  • AbolerIS Pharma — AbolerIS Pharma aims to develop novel and unique therapeutic approaches to induce immune tolerance.
  • Mobile Media Content - TICKETING3D — Mobile Media Content, a Barcelona, Spain-based provider of virtual visualization technologies, raised €400k in seed funding.Founded in May 2012 by Michele Marino, CEO and Francis Casado, Head of Business Development, Mobile Media Content provides TICKETING3D, a SaaS 3D seating chart of a venue, which allows the final user to check the view fromhis seat before purchasing a ticket. It also Tranfer3D, which lets any club or sports organization to move supporters or fans from one location to another, and Match3D, a 2nd screening tool that allows following matches in real time.The company currently employs 20 people
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
GM&C Life Sciences Fund
VC Fund · Alderley Edge, Cheshire, United Kingdom · 19 investments in Europe Biotechnology startups

The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Medical
  • Stage:Seed, Series A
  • Geography: United Kingdom, Italy, Germany

Investor stats

  • Total investments: 32
  • Round size: Seed $61k–$903k
  • Lead/follow: 69% lead, 31% follow

Portfolio highlights

  • ScubaTx — ScubaTx is a breakthrough organ preservation device organ transplant. The ScubaTx device will leverage world-leading expertise in software design to commercialise a proven but unexploited organ preservation technique, Persufflation. ScubaTx will offer healthcare providers significant net savings, an
  • Flynotes — Flynotes is a digital software platform helping dentists deliver personalised patient care
  • QV Bioelectronics — Manchester-based start-up QV Bioelectronics is developing innovative electrotherapy devices for the treatment of certain types of brain tumours.
Show all investments...

BioInnovation Institute
VC Fund · Copenhagen, Hovedstaden, Denmark · 19 investments in Europe Biotechnology startups, 16 in the past 12 months

BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.

Show more...

Investment focus

  • Industry: Biotechnology, Medical, Health Care
  • Stage:Convertible Note, Debt Financing, Pre-Seed
  • Geography: Denmark, Germany, Switzerland

Investor stats

  • Total investments: 65
  • Round size: Pre-Seed $504k–$1.8M; Debt Financing $536k–$1.4M; Convertible Note $536k–$1.4M
  • Lead/follow: 92% lead, 8% follow

Portfolio highlights

  • TriptoBIO — TriptoBIO is developing a platform for producing natural plant compounds that will support the health of our planet. Our goal is to create a future where everyone can benefit from the power of plants, without depleting natural resources. Our first compound will liberate the world from rat poison
  • MATR Foods — MATR Foods is a food-tech startup that provides fungi-based food ingredients offering dishes produced from fungi like mushrooms, vegetables, and fruits.
  • Agrobiomics — Agrobiomics is a danish Agritech start-up, harnessing the power of soil bacteria and their metabolites as new biostimulants to help crops cope with abiotic stress such as drought.
Show all investments...

Newable Private Investing
VC Fund · London, England, United Kingdom · 18 investments in Europe Biotechnology startups

Newable helps businesses thrive through funding, professional support and premises. Unleashing potential, building resilience & championing growth.

Show more...

Investment focus

  • Industry: Software, Health Care, Biotechnology
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States

Investor stats

  • Total investments: 100
  • Round size: Seed $184k–$2.9M; Series A $1.2M–$3.8M
  • Lead/follow: 23% lead, 77% follow
  • Last fund: May invest from a new fund soon — last raise in 2019

Portfolio highlights

  • Delta g — Delta g Limited is a quantum technology and gravity gradiometry company. A spin-out from the University of Birmingham our technology has applications in industries as varied as civil engineering, infrastructure, defence, rail, navigation and resource exploration. Experts from science, engineering an
  • EarSwitch — Empowering new ways to control and connect with the world through in-ear biometric switch and sensor technology
  • RAB Microfluidics — We diagnose early signs of failure in lubricated machinery and prevent equipment failure using our patented microfluidic technology and AI technology.
Show all investments...

Centre for the Development of Industrial Technology (CDTI)
VC Fund · Madrid, Madrid, Spain · 18 investments in Europe Biotechnology startups, 13 in the past 12 months

The Center for Industrial Technological Development (CDTI) is a public corporation under the Ministry of Economy and Competitiveness, which promotes innovation and technological development of Spanish companies. Is the entity which channels requests for funding and support to projects I + D + i of Spanish companies in the national andinternational levels. The CDTI has a staff of more than 300 people formed three quarters of engineers and graduates. Although the bulk of the infrastructure of the CDTI is located in Madrid, the Centre offers Spanish companies a strategic network of offices and representatives abroad (Japan -SBTO (Spain Business and Technology Office) - Belgium -SOST (Spain Office of Science and Technology) and Permanent Secretariat Eureka-, Brazil -FINEP (Financier of Studies and Projects) -, Korea, Chile, Morocco, China, India, Mexico and USA) to support them in their technological activities of type int .

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Software
  • Stage:Seed, Grant
  • Geography: Spain, United States, France

Investor stats

  • Total investments: 106
  • Round size: Seed $536k–$4.4M; Grant $123k–$841k
  • Lead/follow: 35% lead, 65% follow

Portfolio highlights

  • inari — INARI provides blockchain, machine learning and artificial intelligence technologies for the Insurance industry
  • Candam — Candam is a technology company that provides innovative technological solutions for rewarding and refund of disposable waste.
  • wooptix — Wooptix is a developer of light field and wavefront phase imaging platform designed to acquire all information about the light using
Show all investments...

Development Bank of Wales
VC Fund · Cardiff, Cardiff, United Kingdom · 18 investments in Europe Biotechnology startups, 11 in the past 12 months

Development Bank of Wales is formed in 2001 by the Welsh Assembly Government. Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.

Show more...

Investment focus

  • Industry: Health Care, Software, Biotechnology
  • Stage:Seed, Debt Financing
  • Geography: United Kingdom, Australia, United States

Investor stats

  • Total investments: 149
  • Round size: Seed $307k–$1.8M; Debt Financing $12k–$2.8M
  • Lead/follow: 58% lead, 42% follow
  • Last fund: May invest from a new fund soon — last raise in 2018

Portfolio highlights

  • CanSense — CanSense is a developer of an inexpensive and scalable blood test intended for early diagnosis of bowel cancer.
  • Stratigens — Talent intelligence software| external people analytics | Diversity, location planning and skills data to inform strategy | Data based decision making
  • 2B Enterprising — 2B Enterprising offers an enterprise education program for primary schools that aims to inspire next generation and foster an entrepreneurial mindset.
Show all investments...

HealthCap
VC Fund · Stockholm, Stockholms Lan, Sweden · 18 investments in Europe Biotechnology startups

HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series A
  • Geography: United States, Sweden, France

Investor stats

  • Total investments: 109
  • Round size: Series A $5.5M–$55M; Series B $20M–$54M
  • Lead/follow: 25% lead, 75% follow
  • Last fund: May invest from a new fund soon — last raise in 2019

Portfolio highlights

  • Hemab — Hemab is pioneering the first preventative treatments and functional cures for patients with rare bleeding and thrombotic disorders.
  • ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
  • Vicore Pharma — Vicore Pharma is a pharmaceutical company dedicated to developing innovative medicines for severe lung disorders. It develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EUand the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. The company is based in Astra Zeneca’s Bioventurehub in Mölndal.
Show all investments...

IP Group
VC Fund · London, England, United Kingdom · 17 investments in Europe Biotechnology startups, 9 in the past 12 months

IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Therapeutics
  • Stage:Seed, Series A, Series B
  • Geography: United Kingdom, United States, Australia

Investor stats

  • Total investments: 157
  • Round size: Seed $369k–$6.4M; Series A $1.8M–$17M; Series B $7.4M–$61M
  • Lead/follow: 24% lead, 76% follow
  • Last fund: May invest from a new fund soon — last raise in 2014

Portfolio highlights

  • AccelerComm — Our patented, market-leading IP solutions for 4G and 5G are configurable for quick, high-performance implementations across a wide range of applications.
  • Deep Render — Deep Render Ltd. is a spin-out from the Department of Computing at Imperial College London. We are a London based AI start-up that is developing the next generation of media compression algorithms. Our proprietary and patented technology is at the forefront of machine learning research. Furthermore, our Biological Image Compression results arestate-of-the-art, providing at least a 50% efficiency gain over the previous standards
  • Crescendo Biologics — Crescendo Biologics is a new Cambridge-based company whose vision is to deliver next-generation antibody therapeutics based on novel class-leading platforms.The focus of the company is on developing platforms that will address key issues in generating high-affinity, soluble, human VH antibody fragments. These are the smallest fragments thatretain antibody binding, and have many desirable properties as potential therapeutics. Crescendo will then utilise these platforms for product development of in-house targets or in partnership with other companies.
Show all investments...

Kelvin Capital
VC Fund · Glasgow, Glasgow City, United Kingdom · 17 investments in Europe Biotechnology startups

We invest venture capital in to globally ambitious companies which have the potential to deliver a significant return to our investors

Show more...

Investment focus

  • Industry: Health Care, Biotechnology, Manufacturing
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States

Investor stats

  • Total investments: 72
  • Round size: Seed $139k–$1.1M; Series A $1.6M–$24M
  • Lead/follow: 49% lead, 51% follow

Portfolio highlights

  • novosound — Novosound is an award winning Scottish sensors company utilising thin-film processes to eliminate conventional limitations in ultrasound sensors.
  • Snappy Shopper — Order your favourite products from your local convenience store, for delivery from as little as 30 minutes with Snappy Shopper. Your every day essentials are only a click away - order your grocery delivery online or through our app.
  • Sofant Technologies — Sofant is developing a low cost RF MEMS technology that solves power consumption and heat problems in high frequency phased array antenna systems.
Show all investments...

AdBio partners
VC Fund · Paris, Ile-de-France, France · 16 investments in Europe Biotechnology startups, 6 in the past 12 months

AdBio partners is a European Life Sciences Venture Capital firm dedicated to seeding healthcare’s step forward.We work with leading research institutions and well-established technology transfer offices, with a strong network of scientific and medical partners, exploring new territories to source breakthrough medical discoveries and driveinventive Life Sciences start-ups to success.We embrace European Life Sciences’ dynamic of innovation. Europe harbors a vibrant environment for medical and scientific investigation, with some of the most leading-edge academic and research centers. AdBio partners seizes the opportunity to highlight their undervalued research programs and assets and participate in structuring Europe’s biotechnology ecosystem.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Seed, Series A
  • Geography: France, Belgium, Spain

Investor stats

  • Total investments: 21
  • Round size: Seed $2.1M–$5.9M; Series A $20M–$29M
  • Lead/follow: 52% lead, 48% follow
  • Last fund: Likely still investing — raised $106M in 2021

Portfolio highlights

  • Astraveus — Designing and building closed, automated, bioprocessing systems for the production of cell and gene therapies.
  • Orikine Bio — Orikine Bio is a pioneer biotech company in the field of tailored cytokines with unmatched biological properties for the treatment of immune-mediated disorders.
  • Anoat Therapeutics — Anoat Therapeutics develops an innovative, disease-modifying approach in Cystic Fibrosis.
Show all investments...

TRICAPITAL
VC Fund · Melrose, Scottish Borders, The, United Kingdom · 16 investments in Europe Biotechnology startups

The TRICAPITAL Syndicate is a business angel cohort of entrepreneurs, CEOs and business leaders who have founded, funded and built companies

Show more...

Investment focus

  • Industry: Biotechnology, Software, Health Care
  • Stage:Seed, Series B
  • Geography: United Kingdom, France

Investor stats

  • Total investments: 47
  • Round size: Seed $246k–$1.2M; Series B $172k–$6.4M
  • Lead/follow: 19% lead, 81% follow

Portfolio highlights

  • ŌGI Bio — Offering an affordable route to automating routine microbial culturing with a unique, modular, retrofittable device
  • Carcinotech — Carcinotech is a MedTech company manufacturing 3D printed mini tumours developed from patient-specific cancer stem cells, primary cells and established cell lines.
  • Heero Technologies — Heero Technologies, the leading independent energy platform for making net zero homes a reality
Show all investments...

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!
NRW.BANK
VC Fund · Düsseldorf, Nordrhein-Westfalen, Germany · 15 investments in Europe Biotechnology startups

NRW.BANK is the development bank for the state of North Rhine-Westphalia. It supports its owner – the state of North Rhine-Westphalia – in fulfilling its tasks, notably in the fields of structural, economic, social and housing policy. NRW.BANK pools the promotion and development programmes of the state of North Rhine-Westphalia, the FederalRepublic of Germany and the European Union and combines them with its own equity and debt products and advisory services. It offers the full range of financial products in three areas “Economy”, “Housing”, and “Infrastructure/Municipalities”. NRW.BANK operates in a competitively neutral manner as a partner of banks and savings banks.

Show more...

Investment focus

  • Industry: Biotechnology, Software, Health Care
  • Stage:Seed, Series A, Series B
  • Geography: Germany, United States

Investor stats

  • Total investments: 79
  • Round size: Seed $107k–$7.5M; Series A $2.1M–$13M; Series B $2.7M–$9M
  • Lead/follow: 18% lead, 82% follow
  • Last fund: May invest from a new fund soon — raised $86M in 2011

Portfolio highlights

  • bNear — bNear is the digital space for all distributed- & hybrid teams - Safe and convenient in Microsoft Teams!
  • Companyon Analytics — Companyon Analytics provides data security, cloud infrastructure, information technology, technical solutions, and consultancy services.
  • Refined Laser Systems — Refined Laser Systems is a dynamic biophotonics company.It specialises in creating innovative laser systems for SRS-microscopy and quantum technology.
Show all investments...

Forbion Capital Partners
VC Fund · Naarden, Noord-Holland, The Netherlands · 15 investments in Europe Biotechnology startups, 8 in the past 12 months

Impacting the future of medicine.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series B, Series A, Series C
  • Geography: United States, United Kingdom, The Netherlands

Investor stats

  • Total investments: 118
  • Round size: Series A $4.5M–$30M; Series B $12M–$115M; Series C $5.6M–$65M
  • Lead/follow: 46% lead, 54% follow
  • Last fund: Likely still investing — fund raised in 2023

Portfolio highlights

  • Mariana Oncology — Mariana Oncology is a biotechnology research industry.
  • Seamless Therapeutics — Seamless Therapeutics is changing the paradigm of gene editing through a pioneering approach to restore health in patients with severe conditions in a safe and precise manner. Seamless technology platform unlocks the reprogramming of recombinases, a highly versatile class of enzymes.
  • Complement Therapeutics — Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Turning powerful new Complement System insights into innovative treatments Developing the next generation of complement medicines [chevron-down] Geographic atrophy (late dry age-related macular degeneration) is a chronic eye condition that affects millions - and for which there is
Show all investments...

Par Equity
VC Fund · Edinburgh, Edinburgh, City of, United Kingdom · 15 investments in Europe Biotechnology startups, 11 in the past 12 months

Founded in 2008, Par Equity is a venture capital firm that backs the most innovative, high growth technology companies in the North of the UK. Based in Edinburgh, Par invests across Northern England, Northern Ireland and Scotland.

Show more...

Investment focus

  • Industry: Software, Information Technology, Computer
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States, Brazil

Investor stats

  • Total investments: 163
  • Round size: Seed $244k–$4.7M; Series A $1.6M–$7.9M
  • Lead/follow: 56% lead, 44% follow
  • Last fund: May invest from a new fund soon — last raise in 2020

Portfolio highlights

  • Plotbox — Award winning Cemetery and Crematory management software that enables world class death care facility operations. Fully integrated software and true digital mapping solve long standing problems and accelerates business development. Various packages available.
  • Partful — Make sure customers get the right parts first time, every time with digital 3D parts catalogue software and digital work instructions.
  • Manus Neurodynamica — Manus Neurodynamica is a triage device to support early diagnostics in Parkinson's disease.
Show all investments...

Wellcome Trust
VC Fund · London, England, United Kingdom · 15 investments in Europe Biotechnology startups

Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Pharmaceutical
  • Stage:Grant, Series C
  • Geography: United States, United Kingdom, Germany

Investor stats

  • Total investments: 109
  • Round size: Grant $1.2M–$6.8M; Series C $10M–$90M
  • Lead/follow: 36% lead, 64% follow
  • Last fund: May invest from a new fund soon — last raise in 2018

Portfolio highlights

  • Vaxxas — Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.
  • DataDotOrg — data.org brings together philanthropy, technology, academia, and social impact organizations to build the field of data science for social impact.
  • Feinstein Institute for Medical Research — Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes ofbehavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.
Show all investments...

Elaia
VC Fund · Paris, Ile-de-France, France · 15 investments in Europe Biotechnology startups, 15 in the past 12 months

Elaia is French venture capital firm focused on European digital and deep tech startups, from early stage to growth developpement. We back tech disruptors.

Show more...

Investment focus

  • Industry: Software, Information Technology, Artificial Intelligence
  • Stage:Seed, Series A, Series B
  • Geography: France, United States, Spain

Investor stats

  • Total investments: 151
  • Round size: Seed $857k–$5.4M; Series A $2M–$21M; Series B $3.5M–$27M
  • Lead/follow: 51% lead, 49% follow
  • Last fund: Likely still investing — fund raised in 2022

Portfolio highlights

  • Aviwell — Aviwell’s mission is to develop healthy, native, natural, and sustainable solutions to improve animal health and growth to better nourish the planet ... At a fraction of the cost.
  • Hema.to — Hema.to provides fully automated, AI-powered blood cancer detection suggestions based on flow cytometry data.
  • Greenbids — Reducing digital advertising carbon emissions with machine learning.
Show all investments...

Kernel Capital
VC Fund · Cork, Cork, Ireland · 15 investments in Europe Biotechnology startups

Kernel Capital is the independent manager of The Bank of Ireland Kernel Capital Venture Funds, one of the largest and most active sources of equity finance on the island of Ireland. Kernel leverage their extensive network to enable their portfolio companies recruit the highest caliber people, to break into new international markets and to generaterevenues of scale. It is the only investment firm with venture capital Funds dedicated to both jurisdictions on the Island. Kernel have raised over €210M from investors which including their strategic partner Bank of Ireland, Invest NI, Enterprise Ireland, Galway University Foundation, The University of Limerick Foundation, The New York State Common Retirement Fund and undisclosed Family Offices. Consistently delivering strong financial returns for their investors Kernel have led more than 20 substantial trade sales to NASDAQ, NYSE, and LSE listed corporations.

Show more...

Investment focus

  • Industry: Software, Information Technology, Health Care
  • Stage:Seed, Series A
  • Geography: Ireland, United Kingdom, France

Investor stats

  • Total investments: 86
  • Round size: Seed $536k–$4.3M; Series A $1.4M–$9M
  • Lead/follow: 50% lead, 50% follow
  • Last fund: May invest from a new fund soon — last raise in 2013

Portfolio highlights

  • Pretto — Pretto is the only truly transparent online real estate price comparator.Pretto accompanies you until the signing of your loan, free of charge and without commitment.
  • Pilot Photonics — Welcome to Pilot Photonics, a laser product development company in Dublin, Ireland. We provide optical frequency combs and tunable lasers.
  • Causeway Sensors — The Affinity, is a compact, bench-top Biosensor providing accurate real-time analysis at an accessible price. The Affinity biosensor and accompanying Access Chip incorporate the latest advancements in Nanotechnology, providing the biochemistry researcher the perfect platform to explore the complex world of biomolecular interactions.
Show all investments...

Cambridge Angels group
VC Fund · Cambridge, Cambridgeshire, United Kingdom · 15 investments in Europe Biotechnology startups

The Cambridge Angels are a group of high-net worth investors who have proven experience as successful entrepreneurs in internet, software, technology and bio-technology. Members invest in and mentor high quality start-up and early-stage companies in these sectors in the Cambridge (UK) area and throughout the UK.Typical funding requirements thatthe Cambridge Angels meet are in the range of £50,000 to £500,000 - although it is worth noting that several of their portfolio companies have received more than £1m in funding from their Members over several funding rounds.Their Members have been responsible for a large number of the “Cambridge Phenomenon” success stories over recent years. Therefore, in addition to providing funding for early-stage companies, the Cambridge Angels also offer start-ups the considerable benefit of a wide range of expertise, contacts and directly relevant experience in establishing and growing entrepreneurial businesses successfully.

Show more...

Investment focus

  • Industry: Software, Health Care, Biotechnology
  • Stage:Seed, Series A
  • Geography: United Kingdom, United States, Estonia

Investor stats

  • Total investments: 116
  • Round size: Seed $244k–$2.5M; Series A $983k–$16M
  • Lead/follow: 15% lead, 85% follow

Portfolio highlights

  • Molymem — Molymem enhances the performance of filtering membranes used in separation processes including desalination and the removal of industrial contaminants.
  • Silveray — Silveray develop affordable large-area direct conversion detectors for the X-ray imaging market.
  • Five Alarm Bio — Five Alarm Bio is a drug discovery company. Five Alarm intends to use discoveries to provide secure and efficient remedies for a variety of age-related illnesses and limitations. Five Alarm Bio is creating a small molecule strategy to strengthen the body's defense against aging.
Show all investments...

EQT life science
VC Fund · Amsterdam, Noord-Holland, The Netherlands · 15 investments in Europe Biotechnology startups

EQT life science develops innovative medicines, devices, and tools to address the single important thing that matters to the preservation of health. The organization believes that such opportunities add value to all stakeholders.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Therapeutics
  • Stage:Series A, Series B, Series C
  • Geography: United States, The Netherlands, Switzerland

Investor stats

  • Total investments: 129
  • Round size: Series A $6.4M–$50M; Series B $5.4M–$69M; Series C $10M–$70M
  • Lead/follow: 36% lead, 64% follow
  • Last fund: Likely still investing — raised $279M in 2023

Portfolio highlights

  • Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
  • QurAlis — QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS .
  • Evommune — Evommune is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
Show all investments...

Vaekstfonden
VC Fund · Hellerup, Hovedstaden, Denmark · 15 investments in Europe Biotechnology startups, 13 in the past 12 months

Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.

Show more...

Investment focus

  • Industry: Software, Information Technology, SaaS
  • Stage:Seed, Pre-Seed
  • Geography: Denmark, United States, United Kingdom

Investor stats

  • Total investments: 188
  • Round size: Seed $790k–$4.6M; Pre-Seed $431k–$1.2M
  • Lead/follow: 29% lead, 71% follow

Portfolio highlights

  • Wedio — Buy & Rent professional film equipment from trusted creators near you. Buy & rent cameras, lenses, drones with Global Coverage. Explore
  • QuadSAT — QuadSAT provides antenna and RF measurements with state-of-the-art equipment, including a drone platform with payload and custom software.
  • kleen hub — Kleen hub is Denmark's first digital return system for reusable coffee cups and food packaging.
Show all investments...

Ysios Capital
VC Fund · San Sebastian, Pais Vasco, Spain · 15 investments in Europe Biotechnology startups

Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.

Show more...

Investment focus

  • Industry: Biotechnology, Health Care, Medical
  • Stage:Series A, Series B, Series C
  • Geography: Spain, United States, Switzerland

Investor stats

  • Total investments: 65
  • Round size: Series A $2.1M–$40M; Series B $17M–$37M; Series C $27M–$48M
  • Lead/follow: 35% lead, 65% follow
  • Last fund: May invest from a new fund soon — last raise in 2020

Portfolio highlights

  • VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
  • Xeltis — Xeltis is pioneering a restorative approach in cardiovascular therapy.
  • ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
Show all investments...

FAQ

Is Shizune data fresh/accurate?

Shizune has monitored hundreds of funding sources since 2020.

Our investor database is updated every day, so investor data is always fresh.

All metrics are calculated from confirmed public rounds, so the data is accurate.

Can I download investor list?

To download the Biotechnology Investors in Europe investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.

You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.

Can I access investor database?

To access all 48,091 investors investing in Europe Biotechnology startups and 48,091+ more investors, create a Shizune account.

Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.

The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.

You can enrich with email and download the data.

Does Shizune have investor emails and contacts?

Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.

To guarantee the highest discovery rate, we search across 20+ contact search tools.

To maximize delivery rate and reduce bounce rate, we validate emails.

You can enrich your investor list with Shizune. Download it too.

What is Shizune?

Shizune is a 48,091 investor database updated daily.

With Shizune you can:

  • browse the database
  • use smart matching
  • enrich with emails
  • download

All you need to find investors for your startup.

Who is Shizune for?

Shizune is built for startup founders by startup founders.

If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.

Is Shizune free?

Shizune is free forever. You can search and browse investors for free.

Email search and export are paid features.

For full info, visit our pricing.

Who built Shizune?

Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.

Contact 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!

More investor lists